Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 885 entries
View as:

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT04030533 Org: User:
Start: 11/29/19 End: 12/31/20 Due: 12/31/21

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT03864601 Org: User:
Start: 04/09/19 End: 06/14/19 Due: 06/14/20

PRILIGY Usage Patterns in Selected Populations

Phase: N/A Priority: Normal
NCT ID: NCT01273545 Org: User:
Start: 01/31/10 End: 12/31/12 Due: 12/31/13

Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01260545 Org: User:
Start: 04/30/11 End: 09/30/12 Due: 09/30/13

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT01655147 Org: User:
Start: 01/31/12 End: 03/31/12 Due: 03/31/13

A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix

Phase: N/A Priority: Normal
NCT ID: NCT04821323 Org: User:
Start: 03/10/21 End: 05/07/21 Due: 05/07/22

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Phase: N/A Priority: Normal
NCT ID: NCT03586843 Org: User:
Start: 06/29/18 End: 03/17/19 Due: 03/17/20

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT00911859 Org: User:
Start: 06/30/09 End: 04/30/13 Due: 04/30/14

A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants

Phase: N/A Priority: Normal
NCT ID: NCT02071355 Org: User:
Start: 04/30/14 End: 06/30/14 Due: 06/30/15

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT02933580 Org: User:
Start: 10/12/16 End: 02/04/17 Due: 02/04/18

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02413489 Org: User:
Start: 09/02/15 End: 06/01/17 Due: 06/01/18

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04102111 Org: User:
Start: 09/23/19 End: 12/22/21 Due: 12/22/22

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00887198 Org: User:
Start: 04/28/09 End: 05/25/17 Due: 05/25/18

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT02186873 Org: User:
Start: 09/03/14 End: 10/11/16 Due: 10/11/17

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Phase: N/A Priority: Normal
NCT ID: NCT02546960 Org: User:
Start: 11/12/15 End: 06/21/19 Due: 06/21/20

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04181827 Org: User:
Start: 06/12/20 End: 06/30/27 Due: 06/30/28

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT02345148 Org: User:
Start: 12/31/14 End: 01/31/15 Due: 01/31/16

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03652064 Org: User:
Start: 11/06/18 End: 01/09/26 Due: 01/09/27

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02277444 Org: User:
Start: 12/22/14 End: 09/27/24 Due: 09/27/25

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Phase: N/A Priority: Normal
NCT ID: NCT03217812 Org: User:
Start: 11/23/17 End: 03/08/24 Due: 03/08/25

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Phase: N/A Priority: Normal
NCT ID: NCT02203032 Org: User:
Start: 10/07/14 End: 05/24/16 Due: 05/24/17

Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)

Phase: N/A Priority: Normal
NCT ID: NCT03059303 Org: User:
Start: 02/20/17 End: 04/24/17 Due: 04/24/18

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Phase: N/A Priority: Normal
NCT ID: NCT02765490 Org: User:
Start: 11/09/16 End: 11/16/17 Due: 11/16/18

A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment

Phase: N/A Priority: Normal
NCT ID: NCT02419183 Org: User:
Start: 05/31/15 End: 03/31/16 Due: 03/31/17

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04532749 Org: User:
Start: 09/15/20 End: 07/14/22 Due: 07/14/23